Haug Partners’ Biotech Litigation practice is comprised of attorneys with extensive trial and appellate experience, registered patent attorneys, and scientific advisors with advanced degrees in specialized technical fields, coupled with expertise in the biotechnology, biopharmaceutical, and medical device industries.
Led by seasoned trial and appellate lawyer Ed Haug, the Haug Partners Biotech Litigation team has practiced litigation in the biotechnology and biopharmaceutical industries since the firm was founded in 1997. Our team includes attorneys who have served in a number of prominent leadership roles and who have been instrumental to developments in intellectual property law, including attorneys who have served as members of the District of New Jersey Local Rules Committee, President of the Federal Circuit Bar Association, and Lead Administrative Patent Judge at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.
Unlike many of our competitors, at Haug Partners we have worked with both innovator and follow-on drugs, and we are able to counsel clients strategically from both perspectives. Haug Partners’ unique, cross-functional biotechnology and biopharmaceutical litigation, patent litigation, and FDA practices also enable our Biotech Litigation team to provide seamless, interdisciplinary counseling and representation across all phases of a litigation lifecycle, from pre-suit strategy and patent analysis to appeals before the Court of Appeals for the Federal Circuit. Haug Partners regularly appears before federal district courts and other state and federal courts, including the Supreme Court of the United States, where we recently argued a case concerning the scope of the patent exhaustion doctrine in self-propagating technologies.
